CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 85.4% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Close

Trade Vir Biotechnology VIR

Sell
 Buy

VirBiotechnology live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

News

Webhose 2026 Aug 26, 07:20

ADAR1 Capital Management LLC Acquires New Shares in Vir Biotechnology, Inc. $VIR

Vir Biotechnology Inc
Webhose 2026 Aug 25, 12:03

Vir Biotechnology (NASDAQ:VIR) Shares Up 8.1% - Time to Buy? - Stock Observer

Vir Biotechnology Inc
Webhose 2026 Aug 25, 06:41

Parkman Healthcare Partners LLC Takes $4.84 Million Position in Vir Biotechnology, Inc. $VIR - Stock Observer

Vir Biotechnology Inc
Webhose 2026 Aug 18, 01:49

Quantinno Capital Management LP Grows Stake in Vir Biotechnology, Inc. $VIR - Daily Political

Vir Biotechnology Inc
Webhose 2026 Aug 12, 21:28

Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript

Vir Biotechnology Inc
Webhose 2026 Aug 11, 08:14

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages

Vir Biotechnology Inc
Webhose 2026 Aug 11, 04:15

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Rating of "Moderate Buy" from Analysts - Stock Observer

Vir Biotechnology Inc
Webhose 2026 Aug 08, 05:12

Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Wall Street Zen

Vir Biotechnology Inc
Webhose 2026 Aug 07, 15:56

Vir Biotechnology (NASDAQ:VIR) Posts Earnings Results, Beats Expectations By $0.14 EPS - Zolmax

Vir Biotechnology Inc
Webhose 2026 Aug 06, 07:03

Vir Biotechnology Q2 Earnings Call Highlights

Vir Biotechnology Inc
Webhose 2026 Aug 06, 05:08

Vir Biotechnology Inc (VIR) (Q2 2026) Earnings Call Highlights: 88% HDV Cure Rate and a $1B ...

Vir Biotechnology Inc
Webhose 2026 Aug 05, 22:11

Vir Biotechnology (NASDAQ:VIR) Posts Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Vir Biotechnology Inc
Webhose 2026 Aug 05, 08:56

Renaissance Technologies LLC Increases Stake in Vir Biotechnology, Inc. $VIR

Vir Biotechnology Inc
Webhose 2026 Aug 01, 00:59

950,000 Shares in Vir Biotechnology, Inc. $VIR Bought by Avidity Partners Management LP - Daily Political

Vir Biotechnology Inc

VirBiotechnology news

Latest news

Info

Spread

0.14

Spread (%)

1.3060 %

Leverage

1:5

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Monday

13:31 - 19:59

Tuesday

13:31-19:59

Wednesday

13:31-19:59

Thursday

13:31-19:59

Friday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

1832608768

Shares Outstanding

169215958

Earnings Date (Next)

0000-00-00

Div Yield

Ex-Dividend Date

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-1.7

Learn more about this instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now

Latest Education Articles

Trustpilot